Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 4/2018

01-08-2018 | Rare Bone Disease (C Langman and E Shore, Section Editors)

Modeling Rare Bone Diseases in Animals

Authors: Charles A. O’Brien, Roy Morello

Published in: Current Osteoporosis Reports | Issue 4/2018

Login to get access

Abstract

Purpose of Review

The goal of this review is to highlight some of the considerations involved in creating animal models to study rare bone diseases and then to compare and contrast approaches to creating such models, focusing on the advantages and novel opportunities offered by the CRISPR-Cas system.

Recent Findings

Gene editing after creation of double-stranded breaks in chromosomal DNA is increasingly being used to modify animal genomes. Multiple tools can be used to create such breaks, with the newest ones being based on the bacterial adaptive immune system known as CRISPR/Cas.

Summary

Advances in gene editing have increased the ease and speed, while reducing the cost, of creating novel animal models of disease. Gene editing has also expanded the number of animal species in which genetic modification can be performed. These changes have significantly increased the options for investigators seeking to model rare bone diseases in animals.
Literature
1.
Guenet JL, Stanescu R, Maroteaux P, Stanescu V. Fragilitas ossium: a new autosomal recessive mutation in the mouse. J Hered. 1981;72(6):440–1.CrossRefPubMed
2.
Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013;110(9):3507–12.CrossRefPubMedPubMedCentral
3.
Takao K, Miyakawa T. Genomic responses in mouse models greatly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2015;112(4):1167–72.CrossRefPubMed
4.
Morello R, Bertin TK, Chen Y, Hicks J, Tonachini L, Monticone M, et al. CRTAP is required for prolyl 3- hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell. 2006;127(2):291–304.CrossRefPubMed
5.
Ward LM, Rauch F, Travers R, Chabot G, Azouz EM, Lalic L, et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone. 2002;31(1):12–8.CrossRefPubMed
6.
Labuda M, Morissette J, Ward LM, Rauch F, Lalic L, Roughley PJ, et al. Osteogenesis imperfecta type VII maps to the short arm of chromosome 3. Bone. 2002;31(1):19–25.CrossRefPubMed
7.
Tonachini L, Morello R, Monticone M, Skaug J, Scherer SW, Cancedda R, et al. cDNA cloning, characterization and chromosome mapping of the gene encoding human cartilage associated protein (CRTAP). Cytogenet Cell Genet. 1999;87(3–4):191–4.CrossRefPubMed
8.
9.
Morello R and Esposito PW. Osteogenesis Imperfecta. Osteogenesis, Edited by Yunfeng Lin. Published by InTech. 2012;223–52.
10.
Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107(4):513–23.CrossRefPubMed
11.
Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002;70(1):11–9.CrossRefPubMed
12.
Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346(20):1513–21.CrossRefPubMed
13.
Ai M, Holmen SL, Van HW, Williams BO, Warman ML. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol. 2005;25(12):4946–55.CrossRefPubMedPubMedCentral
14.
Semenov MV, He X. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST. J Biol Chem. 2006;281(50):38276–84.CrossRefPubMed
15.
Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Benichou O, Scopelliti D, et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet. 2003;72(3):763–71.CrossRefPubMedPubMedCentral
16.
Jiao X, Ventruto V, Trese MT, Shastry BS, Hejtmancik JF. Autosomal recessive familial exudative vitreoretinopathy is associated with mutations in LRP5. Am J Hum Genet. 2004;75(5):878–84.CrossRefPubMedPubMedCentral
17.
Toomes C, Bottomley HM, Jackson RM, Towns KV, Scott S, Mackey DA, et al. Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q. Am J Hum Genet. 2004;74(4):721–30.CrossRefPubMedPubMedCentral
18.
19.
Kurihara N, Zhou H, Reddy SV, Garcia PV, Subler MA, Dempster DW, et al. Expression of measles virus nucleocapsid protein in osteoclasts induces Paget's disease-like bone lesions in mice. J Bone Miner Res. 2006;21(3):446–55.CrossRefPubMed
20.
21.
• Wang W, Wang H, Zhou X, Li X, Sun W, Dellinger M, et al. Lymphatic endothelial cells produce M-CSF, causing massive bone loss in mice. J Bone Miner Res. 2017;32(5):939–50. This paper reports a novel mouse model that is quite useful for the study of Ghoram-Stout disease. CrossRefPubMedPubMedCentral
22.
Gordon JW, Scangos GA, Plotkin DJ, Barbosa JA, Ruddle FH. Genetic transformation of mouse embryos by microinjection of purified DNA. Proc Natl Acad Sci U S A. 1980;77(12):7380–4.CrossRefPubMedPubMedCentral
23.
Nagy A, Gertsenstein M, Vintersten K, Behringer RR. Manipulating the mouse embryo: a laboratory manual. Third ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2003.
24.
Schipani E, Lanske B, Hunzelman J, Luz A, Kovacs CS, Lee K, et al. Targeted expression of constitutively active receptors for parathyroid hormone and parathyroid hormone-related peptide delays endochondral bone formation and rescues mice that lack parathyroid hormone-related peptide. Proc Natl Acad Sci U S A. 1997;94(25):13689–94.CrossRefPubMedPubMedCentral
25.
Sher LB, Woitge HW, Adams DJ, Gronowicz GA, Krozowski Z, Harrison JR, et al. Transgenic expression of 11 beta-hydroxysteroid dehydrogenase type 2 in osteoblasts reveals an anabolic role for endogenous glucocorticoids in bone. Endocrinology. 2004;145(2):922–9.CrossRefPubMed
26.
Dacic S, Kalajzic I, Visnjic D, Lichtler AC, Rowe DW. Col1a1-driven transgenic markers of osteoblast lineage progression. J Bone Miner Res. 2001;16(7):1228–36.CrossRefPubMed
27.
Krebsbach PH, Harrison JR, Lichtler AC, Woody CO, Rowe DW, Kream BE. Transgenic expression of COL1A1-chloramphenicol acetyltransferase fusion genes in bone: differential utilization of promoter elements in vivo and in cultured cells. Mol Cell Biol. 1993;13(9):5168–74.CrossRefPubMedPubMedCentral
28.
Bogdanovic Z, Bedalov A, Krebsbach PH, Pavlin D, Woody CO, Clark SH, et al. Upstream regulatory elements necessary for expression of the rat COL1A1 promoter in transgenic mice. J Bone Miner Res. 1994;9(2):285–92.CrossRefPubMed
29.
Rossert J, Eberspaecher H, de Crombrugghe B. Separate cis-acting DNA elements of the mouse pro-alpha 1(I) collagen promoter direct expression of reporter genes to different type I collagen-producing cells in transgenic mice. J Cell Biol. 1995;129(5):1421–32.CrossRefPubMed
30.
Dacquin R, Starbuck M, Schinke T, Karsenty G. Mouse alpha1(I)-collagen promoter is the best known promoter to drive efficient Cre recombinase expression in osteoblast. Dev Dyn. 2002;224(2):245–51.CrossRefPubMed
31.
Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res. 2003;18(6):960–74.CrossRefPubMed
32.
Yoshizawa T, Hinoi E, Jung DY, Kajimura D, Ferron M, Seo J, et al. The transcription factor ATF4 regulates glucose metabolism in mice through its expression in osteoblasts. J Clin Invest. 2009;119(9):2807–17.CrossRefPubMedPubMedCentral
33.
Rodda SJ, McMahon AP. Distinct roles for hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development. 2006;133(16):3231–44.CrossRefPubMed
34.
Thomas KR, Capecchi MR. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell. 1987;51(3):503–12.CrossRefPubMed
35.
Doetschman T, Gregg RG, Maeda N, Hooper ML, Melton DW, Thompson S, et al. Targetted correction of a mutant HPRT gene in mouse embryonic stem cells. Nature. 1987;330(6148):576–8.CrossRefPubMed
36.
Sauer B, Henderson N. Site-specific DNA recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc Natl Acad Sci U S A. 1988;85(14):5166–70.CrossRefPubMedPubMedCentral
37.
Rodriguez CI, Buchholz F, Galloway J, Sequerra R, Kasper J, Ayala R, et al. High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat Genet. 2000;25(2):139–40.CrossRefPubMed
38.
Branda CS, Dymecki SM. Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice. Dev Cell. 2004;6(1):7–28.CrossRefPubMed
39.
Daley E, Streeten EA, Sorkin JD, Kuznetsova N, Shapses SA, Carleton SM, et al. Variable bone fragility associated with an Amish COL1A2 variant and a knock-in mouse model. J Bone Miner Res. 2010;25(2):247–61.CrossRefPubMed
40.
• Khan SK, Yadav PS, Elliott G, Hu DZ, Xu R, Yang Y. Induced Gnas(R201H) expression from the endogenous Gnas locus causes fibrous dysplasia by up-regulating Wnt/beta-catenin signaling. Proc Natl Acad Sci U S A. 2018;115(3):E418–27. This study demonstrates an effective approach for cell type-specific expression of a mutant allele. CrossRefPubMed
41.
Durai S, Mani M, Kandavelou K, Wu J, Porteus MH, Chandrasegaran S. Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Res. 2005;33(18):5978–90.CrossRefPubMedPubMedCentral
42.
43.
44.
45.
Singh P, Schimenti JC, Bolcun-Filas E. A mouse geneticist’s practical guide to CRISPR applications. Genetics. 2015;199(1):1–15.CrossRefPubMed
46.
Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34(2):184–91.CrossRefPubMedPubMedCentral
47.
Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013;31(9):822–6.CrossRefPubMedPubMedCentral
48.
Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529(7587):490–5.CrossRefPubMedPubMedCentral
49.
50.
Dominguez AA, Lim WA, Qi LS. Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation. Nat Rev Mol Cell Biol. 2016;17(1):5–15.CrossRefPubMed
51.
Xiong J, Piemontese M, Onal M, Campbell J, Goellner JJ, Dusevich V, et al. Osteocytes, not osteoblasts or lining cells, are the main source of the RANKL required for osteoclast formation in remodeling bone. PLoS One. 2015;10(9):e0138189.CrossRefPubMedPubMedCentral
52.
Kalajzic I, Matthews BG, Torreggiani E, Harris MA, Divieti PP, Harris SE. In vitro and in vivo approaches to study osteocyte biology. Bone. 2013;54(2):296–306.CrossRefPubMed
53.
Chen J, Shi Y, Regan J, Karuppaiah K, Ornitz DM, Long F. Osx-Cre targets multiple cell types besides osteoblast lineage in postnatal mice. PLoS One. 2014;9(1):e85161.CrossRefPubMedPubMedCentral
54.
Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013;152(5):1173–83.CrossRefPubMedPubMedCentral
55.
•• Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013;154(2):442–51. This study demonstrates the feasibility of using a modified Cas9 protein to either stimulate or suppress the expression of an endogenous gene. Importantly, the changes in expression are reversible, unlike recombinase-mediated changes. CrossRefPubMedPubMedCentral
56.
Felder AA, Phillips C, Cornish H, Cooke M, Hutchinson JR, Doube M. Secondary osteons scale allometrically in mammalian humerus and femur. R Soc Open Sci. 2017;4(11):170431.CrossRefPubMedPubMedCentral
57.
58.
Sui T, Yuan L, Liu H, Chen M, Deng J, Wang Y, et al. CRISPR/Cas9-mediated mutation of PHEX in rabbit recapitulates human X-linked hypophosphatemia (XLH). Hum Mol Genet. 2016;25(13):2661–71.PubMed
59.
Yang D, Song J, Zhang J, Xu J, Zhu T, Wang Z, et al. Identification and characterization of rabbit ROSA26 for gene knock-in and stable reporter gene expression. Sci Rep. 2016;6:25161.CrossRefPubMedPubMedCentral
Metadata
Title
Modeling Rare Bone Diseases in Animals
Authors
Charles A. O’Brien
Roy Morello
Publication date
01-08-2018
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 4/2018
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-018-0452-x

Other articles of this Issue 4/2018

Current Osteoporosis Reports 4/2018 Go to the issue

Genetics (M Johnson and S Ralston, Section Editors)

Mouse Cre Models for the Study of Bone Diseases

Craniofacial Skeleton (WE Roberts, Section Editor)

Part II: Temporomandibular Joint (TMJ)—Regeneration, Degeneration, and Adaptation

Craniofacial Skeleton (WE Roberts, Section Editor)

Review of Superelastic Differential Force Archwires for Producing Ideal Orthodontic Forces: an Advanced Technology Potentially Applicable to Orthognathic Surgery and Orthopedics

Craniofacial Skeleton (WE Roberts, Section Editor)

Part I: Development and Physiology of the Temporomandibular Joint

Orthopedic Management of Fractures (S Bukata and L Gerstenfeld, Section Editors)

Origin of Reparative Stem Cells in Fracture Healing

Bone and Joint Pain (T King and S Amin, Section Editors)

Clinical Relevance of Joint Hypermobility and Its Impact on Musculoskeletal Pain and Bone Mass